Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
Quarterly
Activity Report
Quarter ending 30 June 2023
IMAGION BIOSYSTEMS LIMITED
(ASX: IBX)
31 July 2023
Highlights:
MagSense® HER2
Phase 1 Study achieves
enrolment target
MELBOURNE – Imagion Biosystems
(ASX:IBX), a company dedicated to
improving healthcare through the
early detection of cancer, today
released its Appendix 4C Quarterly
Cashflow report and update on
company activities for the quarter
ending 30 June 2023 (Q2 FY2023).
Expands collaboration with
Siemens Healthineers
Dr. Isaac Bright
appointed as CEO
2
“We are delighted with how our MagSense® HER2 breast cancer imaging
technology is progressing and with having achieved our enrollment target
for the Phase 1 study,” commented Imagion’s recently appointed CEO, Dr.
Isaac Bright. “Our clinical data to-date supports our vision that our
targeted nanoparticle technology has the potential to change how MRI can
be used to specifically detect cancer.”
Dr. Bright continues, “Our valuable collaboration with Siemens
Healthineers has been expanded to include Siemens’ U.S. team in
anticipation of Imagion undertaking a multi-site Phase 2 study for the
MagSense® HER2 imaging agent. I look forward to the second half of 2023
as we focus on preparing for the multi-site Phase 2 study in the U.S. as we
conclude the Phase 1 study.”
3
Summary of Activities
MagSense® HER2 Phase 1 Study achieves enrolment target
During the quarter, Imagion’s MagSense® HER2 imaging agent Phase 1 study
(IBI10103) achieved its enrolment target with 13 patients enrolled, meeting the
original goal of 10-15 patients. The Company initiated its plans to close the study
as was indicated at the Company’s AGM held on 25 May 2023.
This was a great achievement for Imagion in its first clinical study, whilst
recruitment was challenging, the Phase 1 study was a success, as MagSense®
HER2 has been well-tolerated and the results are easily interpretable by
radiologists. The Company is now well positioned to move ahead with the
MagSense® HER2 breast cancer program. The Phase 1 study has been
instrumental in revealing the potential clinical utility of the MagSense® HER2
Imaging Agent and confirms that the Company’s targeted nanoparticle
technology has the potential to expand MRI utilization with molecular resolution
in the detection of cancer.
Results of the study will be published in due course and the Company will use
the data in support of an Investigational New Drug (IND) application submission
to the US FDA expected late this year or the beginning of 2024.
4
Expands collaboration with Siemens Healthineers to United States
Imagion extended its collaboration agreement with Siemens Healthineers for an
additional two years, during the quarter in anticipation of Imagion undertaking a
multi-site Phase 2 study for the MagSense® HER2 imaging agent. The companies
have also agreed to collaborate in the United States through Siemens Medical
Solutions USA.
The collaboration allows Siemens to provide expertise to Imagion as they work
together with Imagion’s clinical advisors and investigators to optimize the
Magnetic Resonance Imaging (MRI) protocols in anticipation of Imagion’s
MagSense® clinical studies and provide technical support to clinical sites.
The collaboration in place for the MagSense® Phase 1 study in Australia has been
very valuable and is expected to continue now in this expanded capacity in the
United States.
Dr. Isaac Bright appointed as CEO
Dr. Isaac Bright was appointed as CEO of Imagion in June.
Dr. Bright brings over 20 years of experience as a health
industry executive and venture capitalist in medical
technology, biopharmaceuticals, and oncology-based
molecular diagnostics.
This is an exciting new phase for Imagion and Dr. Bright’s track record in strategic
partnering, financing and M&A are well suited to support the Company’s vision
and drive the next chapter in Imagion’s growth.
Dr. Bright’s appointment followed the retirement of Bob Proulx as CEO, with Mr.
Proulx remaining as Chairman of the Board.
5
Funding initiatives
In June 2023, Imagion received $1.0 million from Mercer Street Global
Opportunity Fund LLC, a U.S. based investment fund managed by Mercer Street
Capital Partners LLC pursuant to the convertible note agreement between the
Company and Mercer announced on the ASX on 7 March 2023.
The Company will use this funding to advance clinical development of the
Company’s lead imaging agent as well as for other general working capital
expenses.
In April 2023, Imagion received $413k as proceeds from its entitlement offer that
was opened in March 2023. The shortfall, of $1.97 million, was placed
subsequent to quarter end on 14 July 2023.
Summary of Cash Flow
Imagion’s cash balance at 30 June 2023 was $0.45 million, a decrease of $4.0
million from the prior quarter. The Company reported an operating cash outflow
of $3.1 million in the quarter, slightly higher than the prior quarter’s operating
cash outflow. This was in line with the Company’s expectations.
Increased research & development outflows ($1.3 million outflow in Q2
compared to $839k in Q1) were partially offset by an increase in receipts from
customers ($392k received in Q2 compared to $85k received in Q1). Other costs
remain relatively consistent to the prior quarter.
6
We anticipate administration and corporate costs to remain relatively consistent
compared to current run-rate through the remainder of 2023. Research and
development costs are expected to increase during the remainder of 2023 as the
MagSense® HER2 Breast Cancer program progresses towards an IND filing and
undertakes activities outlined above. In addition, the Company will also be
planning to advance its development pipeline, and therefore this may add to
research and development expenditures.
Receipts from customers are expected to reduce back to Q1 levels as some recent
larger customer orders have been filled.
In relation to liquidity the Company anticipates receiving up to $5.47 million from
the following financing proceeds in Q3 2023: receipt of $1.97 million under the
shortfall associated with the entitlement offer (this has already been received
subsequent to quarter end); and receipt of its research and development tax
incentive in respect of the 2022 year which is anticipated to be $3.5 million (this
has been lodged with the Australian Taxation Office and although was expected in
Q2 2023 it has taken longer than anticipated due to a standard pre-release review
being conducted by the Australian Taxation Office).
The Company also paid $153k to related parties and their associates. These
payments are related to director fees and executive director salaries.
7
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and precision diagnostic
molecular imaging technology. Combining biotechnology and nanotechnology, the
Company aims to detect cancer and other diseases earlier and with higher
specificity than is currently possible. Imagion Biosystems listed on the Australian
Securities Exchange (ASX) in June 2017.
For further information please visit www.imagionbiosystems.com
Authorisation & Additional information
This announcement was authorised by the Board of Directors of Imagion
Biosystems Limited
U.S. Media Contact:
Australian Media & Investor Relations:
Casie Ost
Casie.ost@imagionbio.com
+1-619-693-4428
WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61 (0) 450648064
8
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Imagion Biosystems Limited
ABN
Quarter ended (“current quarter”)
42 616 305 027
30 June 2023
Consolidated statement of cash flows
Current quarter
$A’000
Year to date
(6 months)
$A’000
392
478
(1,310)
(2,149)
-
-
(23)
(114)
-
-
(e) staff costs
(1,493)
(2,986)
(f)
(696)
(1,282)
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
(a) research and development
(b) product manufacturing and operating
costs
(c) advertising and marketing
(d) leased assets
administration and corporate costs
1.3
Dividends received (see note 3)
-
-
1.4
Interest received
7
16
1.5
Interest and other costs of finance paid
(40)
(81)
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
-
-
1.8
Other (provide details if material)
58
99
1.9
Net cash from / (used in) operating
activities
(3,103)
(6,020)
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(a) entities
-
-
(b) businesses
-
-
(17)
(24)
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
(c) property, plant and equipment
other non-current assets
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
2.2
Current quarter
$A’000
Year to date
(6 months)
$A’000
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
Proceeds from disposal of:
other non-current assets
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
-
-
2.6
Net cash from / (used in) investing
activities
(17)
(24)
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
413
413
1,000
2,500
3.2
Proceeds from issue of convertible debt
securities
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
(166)
(343)
3.5
Proceeds from borrowings
-
-
3.6
Repayment of borrowings
(242)
(548)
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
-
-
3.9
Other (provide details if material)
-
-
3.10
Net cash from / (used in) financing
activities
1,004
2,022
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
2,563
4,446
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
(3,103)
(6,020)
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
(17)
(24)
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
Current quarter
$A’000
Year to date
(6 months)
$A’000
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
1,004
2,022
4.5
Effect of movement in exchange rates on
cash held
6
29
4.6
Cash and cash equivalents at end of
period
454
454
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
454
2,563
5.2
Call deposits
-
-
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
454
2,563
6.
Payments to related parties of the entity and their
associates
Current quarter
$A'000
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
153
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
-
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
7.1
Loan facilities
-
-
7.2
Credit standby arrangements
-
-
7.3
Other (please specify)
15,000
2,500
7.4
Total financing facilities
15,000
2,500
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
12,500
The Company has a $15 million convertible note facility with $12.5 million undrawn at
quarter end. $1.0 million was drawn during the quarter, with total drawn of $2.5 million.
The remaining $12.5 million is approved for drawdown by shareholders (at the Company’s
25 May 2023 AGM) for a period of three months until 25 August 2023 and is then subject to
shareholder approval and/or use of the Company’s 15% placement capacity as well as
mutual consent with the lender and the Company prior to drawdown. The facility is secured
over the Company’s assets and has no coupon payable.
8.
Estimated cash available for future operating activities
$A’000
8.1
Net cash from / (used in) operating activities (item 1.9)
(3,103)
8.2
Cash and cash equivalents at quarter end (item 4.6)
454
8.3
Unused finance facilities available at quarter end (item 7.5)
12,500
8.4
Total available funding (item 8.2 + item 8.3)
12,954
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
4.2
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer: N/A
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer: N/A
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: N/A
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
31 July 2023
Date:
...................................................................................
By the Board of Imagion Biosystems Limited
Authorised by: ...................................................................................
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover